Clinical Potential of Adult Vascular Progenitor Cells
Clinical Potential of Adult Vascular Progenitor Cells
复制标题
DOI：
10.1161/atvbaha.109.198895
复制
发表时间：
2010-06-01
影响因子：
8.7
通讯作者：
Caplice, Noel M.
中科院分区：
文献类型：
--
作者：
Kumar, Arun H. S.;Caplice, Noel M.
在过去的十年中，随着对祖细胞动员、募集和分化的理解的提高，治疗血管和心血管疾病的细胞疗法已经发展。在几项临床前研究中观察到的有益效果促使成人血管祖细胞治疗转化为临床试验。迄今为止，从骨髓和外周血中分离的祖细胞已经在急性心肌梗死和慢性缺血性心肌病的背景下进行了测试，具有中等益处。尽管注射的祖细胞数量相对较少并且在靶区中短期驻留，但仍发生这种治疗效果。因此，间接的好处，如从这些细胞释放的旁分泌因子，已被认为是治疗效果的重要贡献者。已经鉴定了几种额外的内皮、平滑肌、间充质和心脏来源的血管祖细胞，它们可能有助于血管发生。事实上，迄今为止最有效的细胞治疗策略的统一范例似乎是对血管生成的有力支持。在这里，我们讨论了一些祖细胞，目前显示出潜在的心血管治疗，无论是单独或组合。我们着眼于新兴的细胞类型和疾病靶点，这些细胞类型和疾病靶点可能被用于治疗益处，以及可能使临床疗效最大化的未来策略。（Arterioscler Thromb Vasc Biol.2010; 30：1080-1087.）
Cell therapy to treat vascular and cardiovascular diseases has evolved over the past decade with improved understanding of progenitor cell mobilization, recruitment, and differentiation. The beneficial effects seen in several preclinical studies have prompted translation of adult vascular progenitor therapy to clinical trials. To date, progenitor cells isolated from bone marrow and peripheral blood have been tested in the context of acute myocardial infarction and chronic ischemic cardiomyopathy, with moderate benefit. This therapeutic effect occurs despite a relatively small number of injected progenitor cells and short-term residence in the target zone. Thus, indirect benefits, such as paracrine factors released from these cells, have been suggested as significant contributors to therapeutic efficacy. Several additional vascular progenitors of endothelial, smooth muscle, mesenchymal, and cardiac origin have been identified that may contribute to vasculogenesis. Indeed, a unifying paradigm for the most effective cell therapy strategies to date appears to be robust support of angiogenesis. Here we discuss a number of progenitor cells that currently show potential as cardiovascular therapeutics, either singly or in combination. We look at emerging cell types and disease targets that may be exploited for therapeutic benefit and future strategies that may maximize clinical efficacy. (Arterioscler Thromb Vasc Biol. 2010; 30: 1080-1087.)